NFE2L2 and metabolic dysfunction-associated steatotic liver disease: We found a reduced BACE1 expression in fibrotic livers of patients with MASLD, which is in line with the reduced BACE1 mRNA expression in cirrhotic livers [9] and might be associated with upregulated Nrf2 (NFE2L2), known for its negative BACE1 regulation [31], in patients with MASLD [32].